(Q40524584)

21 September 2017

1 reference

title

New approaches to the drug treatment of schizophrenia (English)

1 reference

21 September 2017

New Approaches to the Drug Treatment of Schizophrenia (English)

0 references

1 reference

Reynolds GP

1

1 reference

21 September 2017

Czudek C

series ordinal

2

1 reference

21 September 2017

Gavin P. Reynolds

series ordinal

1

0 references

Carole Czudek

series ordinal

2

0 references

publication date

1 January 1995

1 reference

21 September 2017

1995

0 references

published in

Advances in Pharmacology

1 reference

21 September 2017

volume

32

1 reference

21 September 2017

page(s)

461-503

1 reference

An analysis of behavioural effects produced by drug-induced changes of dopaminergic neurotransmission in the brain

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Selective stimulation of dopamine and noradrenaline autoreceptors by B-HT 920 and B-HT 933, respectively

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Does treatment with haloperidol for 3 weeks produce depolarization block in midbrain dopamine neurons of unanaesthetized rats?

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Reduced glutamate decarboxylase activity in the subthalamic nucleus in patients with tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Responses to apomorphine, amphetamine, and neuroleptics in schizophrenic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Antipsychotic Drug Action in Schizophrenic Patients: Effect on Cortical Dopamine Metabolism After Long-Term Treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Differential performance of acute and chronic schizophrenics in a latent inhibition task.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

High dose diazepam in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Deficits in Small Interneurons in Prefrontal and Cingulate Cortices of Schizophrenic and Schizoaffective Patients

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Increased GABAA receptor binding in superficial layers of cingulate cortex in schizophrenics

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Dopamine autoreceptor agonists in the treatment of schizophrenia and major depression

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Treatment strategies for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Gating and habituation of the startle reflex in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Changes in dopamine D1, D2 and D3 receptor mRNA levels in rat brain following antipsychotic treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Clozapine and sulpiride up-regulate dopamine D3 receptor mRNA levels.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Dopamine D1 (SCH 23390) and D2 (haloperidol) antagonists in drug-naive monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Serotonergic and dopaminergic aspects of neuroleptic-induced extrapyramidal syndromes in nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

The sigma enigma: biochemical and functional correlates emerge for the haloperidol-sensitive sigma binding site

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Pharmacological effects of a specific dopamine D-1 antagonist SCH 23390 in comparison with neuroleptics

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Dopamine receptor agonists: mechanisms underlying autoreceptor selectivity. II. Theoretical considerations

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Changes in rat striatal dopamine turnover and receptor activity during one years neuroleptic

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Serotonergic involvement with neuroleptic catalepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Effects of the 5-HT3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Pharmacological properties of SDZ 208-912: a potential high potency, non-classical neuroleptic

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Molecular pathology of schizophrenia: more than one disease process?

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Apomorphine has no effect on plasma homovanillic acid in schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Apomorphine disrupts the inhibition of acoustic startle induced by weak prepulses in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Partial benzodiazepine agonists in schizophrenia: expectations and present clinical findings

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Amperozide and conditioned behaviour in rats: potentiation by classical neuroleptics and alpha-methylparatyrosine

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

No D2 receptor increase in PET study of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Clinical effects of apomorphine in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

SCH 23390 dissociated from conventional neuroleptics in apomorphine climbing and primate acute dyskinesia models

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

New Antipsychotics: Classification, Efficacy, and Adverse Effects

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Startle response models of sensorimotor gating and habituation deficits in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Behavioural pharmacology of 5-HT3 receptor antagonists: a critical update on therapeutic potential

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Antidyskinetic action of 3-PPP, a selective dopaminergic autoreceptor agonist, in Cebus monkeys with persistent neuroleptic-induced dyskinesias

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Evidence for involvement of N-methyl-D-aspartate receptor in tonic inhibitory control of dopaminergic transmission in rat medial frontal cortex.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Central dopamine receptor agonist and antagonist actions of the enantiomers of 3-PPP.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Evidence for coexistence of dopamine and CCK in meso-limbic neurones

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

R-(+)-HA-966, a glycine/NMDA receptor antagonist, selectively blocks the activation of the mesolimbic dopamine system by amphetamine

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Pharmacological profile of the atypical neuroleptic sertindole

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Neuropharmacology: Pathophysiology of schizophrenia — causal role for dopamine or noradrenaline?

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Recent advances in the phencyclidine model of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Glutamate stimulates dopamine release from cortical and limbic rat brain in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Multiple receptors for dopamine

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Transdihydrolisuride, a partial dopamine receptor antagonist: effects on monoamine metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

The biochemistry and pharmacology of mesoamygdaloid dopamine neurons

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Selective D1 and D2 receptor manipulation in Cebus monkeys: relevance for dystonia and dyskinesia in humans.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Benzodiazepine receptors increase in post-mortem brain of chronic schizophrenics

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Antipsychotic efficacy of the dopaminergic autoreceptor agonist EMD 49980 (Roxindol). Results of an open clinical study

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Biochemical pharmacology of the atypical neuroleptic remoxipride

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Neuroleptic-like disruption of the conditioned avoidance response requires destruction of both the mesolimbic and nigrostriatal dopamine systems.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Neuroleptic-induced deficit syndrome: old problem, new challenge

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Neurochemical effects of chronic co-administration of ritanserin and haloperidol: comparison with clozapine effects.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Novel antipsychotic drugs share high affinity for sigma receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

A double-blind multicentre study comparing remoxipride, two and three times daily, with haloperidol in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

The D1 receptor antagonist, SCH 23390, induces signs of parkinsonism in African green monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

The symptoms of chronic schizophrenia. A re-examination of the positive-negative dichotomy

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Benzodiazepines in the treatment of schizophrenia: an updated survey

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Delayed effects of neonatal hippocampal damage on haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Alpha-tocopherol in tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Chronic treatment with the D1 receptor antagonist, SCH 23390, and the D2 receptor antagonist, raclopride, in cebus monkeys withdrawn from previous haloperidol treatment. Extrapyramidal syndromes and dopaminergic supersensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

The effects of neuropeptides on discrete-trial conditioned avoidance responding

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

SCH-23390: a selective D1 dopamine antagonist with potent D2 behavioral actions

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Effects of NMDA receptor ligands on sensorimotor gating in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Dopaminergic stimulation disrupts sensorimotor gating in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Clozapine has sub-micromolar affinity for 5-HT1A receptors in human brain tissue.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Effect of typical and atypical antipsychotic drugs on 5-HT2 receptor density in rat cerebral cortex

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Differential effects of acute and chronic administration of haloperidol on homovanillic acid levels in discrete dopaminergic areas of rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Disorders of attention and perception in early schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

The reversal of extrapyramidal side effects with SCH 39166, a dopamine D1 receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Absence of receptor reserve at striatal dopamine receptors regulating cholinergic neuronal activity

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Anti-muscarinic properties of neuroleptics and drug-induced Parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Expression and characterization of human D4 dopamine receptors in baculovirus-infected insect cells

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Dopaminergic behaviour stereospecific promoted by the D1 agonist R-SK & F 38393 and selectively blocked by the D1 antagonist SCH 23390

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

The enantiomers of SK&F 83566, a new selective D-1 dopamine antagonist, stereospecifically block stereotyped behaviour induced by apomorphine and by the selective D-2 agonist RU 24213.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Antagonism of apomorphine-induced yawning by SCH 23390: evidence against the autoreceptor hypothesis

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Zacopride in schizophrenia: a single-blind serotonin type 3 antagonist trial

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Antagonism of the amphetamine cue by both classical and atypical antipsychotic drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

The effect of the partial dopamine agonist terguride on negative symptoms in schizophrenics

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Increased dopamine-receptor sensitivity in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Acute exacerbation of psychosis with buspirone?

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Effects of several partial dopamine D2 receptor agonists in Cebus apella monkeys previously treated with haloperidol

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Aplastic anaemia and remoxipride

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Propranolol in Schizophrenia: A Double Blind, Placebo Controlled Trial of Propranolol as an Adjunct to Neuroleptic Medication

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Special antagonism of amphetamine-induced abnormal behaviour. Inhibition of stereotyped activity with increase of some normal activities

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Increased concentrations and lateral asymmetry of amygdala dopamine in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Beyond the dopamine hypothesis. The neurochemical pathology of schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Hippocampal benzodiazepine receptors in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Thioridazine is not specific for limbic dopamine receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Chronic clozapine treatment of rats down-regulates cortical 5-HT2 receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Deficit and hemispheric asymmetry of GABA uptake sites in the hippocampus in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

[3H]ditolylguanidine binding to human brain sigma sites is diminished after haloperidol treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Dopamine receptor abnormalities in the striatum and pallidum in tardive dyskinesia: a post mortem study

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Schizophrenia: a neuropathological perspective

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Peptides, the limbic lobe and schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Seroquel: biochemical profile of a potential atypical antipsychotic.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Hippocampal dysgenesis in mutant mouse and schizophrenic man: is there a relationship?

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Animal models for schizophrenia: the hippocampally lesioned animal.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

5-HT2 receptors exert a state-dependent regulation of dopaminergic function: studies with MDL 100,907 and the amphetamine analogue, 3,4-methylenedioxymethamphetamine

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Receptor occupancy by ritanserin and risperidone measured using ex vivo autoradiography

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

SCH23390 causes persistent antidopaminergic effects in vivo: evidence for longterm occupation of receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Antipsychotic drug doses and neuroleptic/dopamine receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Dopamine D4 receptors elevated in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

A subpopulation of dopaminergic neurons in rat ventral mesencephalon contains both neurotensin and cholecystokinin

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

The central effects of a novel dopamine agonist

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Biochemical and functional studies on EMD 49,980: a potent, selectively presynaptic D-2 dopamine agonist with actions on serotonin systems

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Dopamine D4 receptor subtypes and response to clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Dopamine Auto- and Postsynaptic Receptors: Electrophysiological Evidence for Differential Sensitivity to Dopamine Agonists

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Effect of apomorphine on schizophrenic symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Different populations of GABAergic neurons in the visual cortex and hippocampus of cat contain somatostatin- or cholecystokinin- immunoreactive material

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Possible Etiology of Schizophrenia: Progressive Damage to the Noradrenergic Reward System by 6-Hydroxydopamine

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Two dopamine receptors: biochemistry, physiology and pharmacology

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Are neostriatal dopamine receptors co-localized?

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Clozapine and haloperidol in an animal model of sensorimotor gating deficits in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Central dopamine hyperactivity in rats mimics abnormal acoustic startle response in schizophrenics.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Schizophrenic-like sensorimotor gating abnormalities in rats following dopamine infusion into the nucleus accumbens.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Treatment of schizophrenia with ergot derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Interactions between dopamine and 5-HT3 receptors suggest new treatments for psychosis and drug addiction

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Ritanserin, a 5-HT2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Norepinephrine in acute exacerbations of chronic schizophrenia. Negative symptoms revisited

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

In rats, the behavioral profile of CCK-8 related peptides resembles that of antipsychotic agents.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Multiple dopamine D4 receptor variants in the human population

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

New uses of anticonvulsant drugs in psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Dual action on central dopamine function of transdihydrolisuride, a 9, 10-dihydrogenated analogue of the ergot dopamine agonist lisuride

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Glutamate: a new target in schizophrenia?

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Therapeutic potential of selective D-1 dopamine receptor agonists and antagonists in psychiatry and neurology

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Suppression of conditioned avoidance behavior by the local application of (-)sulpiride into the ventral, but not the dorsal, striatum of the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Interaction of the atypical neuroleptic clozapine with 5-HT3 receptors in the cerebral cortex and superior cervical ganglion of the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Selective loss of cerebral cortical Sigma, but not PCP binding sites in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Differential Effects of Classical and Atypical Antipsychotic Drugs on A9 and A10 Dopamine Neurons

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

A lever-release version of the conditioned avoidance response paradigm: effects of haloperidol, clozapine, sulpiride, and BMY-14802

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Ondansetron in treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

B-HT 920--a novel dopamine autoreceptor agonist in the treatment of patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Alprazolam augmentation of the antipsychotic effects of fluphenazine in schizophrenic patients. Preliminary results.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

Propranolol as an adjunct to the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961020-0

7 January 2021

10.1016/S1054-3589(08)61020-0

Identifiers

DOI

0 references

1 reference